Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation (Q38647717)

5 September 2017

title

Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation (English)

1 reference

5 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607297 AND SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Yutaka Seino

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607297 AND SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

25 November 2015

1 reference

Expert Opinion on Drug Safety

5 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607297 AND SRC:MED&resulttype=core&format=json

7 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607297 AND SRC:MED&resulttype=core&format=json

7 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607297 AND SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

249-264

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607297 AND SRC:MED&resulttype=core&format=json

Projections of global mortality and burden of disease from 2002 to 2030

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Obesity and type 2 diabetes in children: epidemiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Causes of death in Japanese diabetics: A questionnaire survey of 18,385 diabetics over a 10-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Economic costs of diabetes in the U.S. in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

The cost of diabetes in adults in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Incretin Therapy – Present and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Alogliptin benzoate for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Incretin physiology and pathophysiology from an Asian perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Immunoassays for the incretin hormones GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Postmenopausal hormone therapy for disease prevention: have we learned any lessons from the past?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

DPP-4 inhibitors: pharmacological differences and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Risk of development of acute pancreatitis with pre-existing diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Fear of hypoglycemia: quantification, validation, and utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Incretin-mimetic therapies and pancreatic disease: a review of observational data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Incretin actions beyond the pancreas: lessons from knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

GIP and GLP-1, the two incretin hormones: Similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2016.1125467

10.1517/14740338.2016.1125467

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26607297 AND SRC:MED&resulttype=core&format=json

7 June 2020

1 reference